Puma Biotechnology
Articles about Puma Biotechnology
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Puma Biotechnology, Inc. (PBYI) Company Information - Simply Wall St
Puma Biotechnology, Inc. 2022 Q4 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology, Inc.
Maximo Nougues - Chief Financial Officer - Puma Biotechnology, Inc. | LinkedIn
Should You Buy Puma Biotechnology Inc (PBYI) Stock After it Has Gained 6.09% in a Week?
Puma Biotechnology, Inc. (NASD:PBYI) Seasonal Chart | Equity Clock
Puma Biotechnology Inc (PBYI) Stock Price & Performance 2023
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
Henry Kuo - Head of Information Technology - Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
Puma Biotechnology
Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Can Puma Biotechnology Inc (PBYI) Stock Rise to the Top of Healthcare Sector Tuesday?
Puma Biotechnology Inc
Puma Biotechnology
With 53% institutional ownership, Puma Biotechnology, Inc. (NASDAQ:PBYI) is a favorite amongst the big guns | Nasdaq
Puma Biotechnology (PBYI) - 5 Price Charts 2012-2023 (History)
Puma Biotechnology, Inc.
